Why “reprogramming” is the buzziest approach to reversing aging right now

Life Biosciences dosed the first glaucoma patient with an experimental "reprogramming" therapy, aiming to regenerate optic nerves. This signals a pivot from treating symptoms to reversing cellular aging. For the 2026 AI economy, it underscores accelerating biotech-AI convergence, where machine learning optimizes reprogramming protocols, potentially unlocking a multi-billion-dollar market in age-related therapeutics.